

the CEC. The Committee is authorized under Article 18 of the North American Agreement on Environmental Cooperation, North America Free Trade Implementation Act, P.L. 103-182 and is directed by Executive Order 12915, entitled "Federal Implementation of the North American Agreement on Environmental Cooperation." The Committee is responsible for providing advice to the U.S. Representative on implementation and further elaboration of the agreement.

The Committee consists of a group of 10 representatives drawn from state, local and tribal governments.

**DATES:** The Committee will meet on March 5, 1998 from 8:30 a.m. to 5:00 p.m. and March 6, 1998 from 8:00 a.m. to 4:30 p.m.

**ADDRESSES:** The Horton Grand Hotel, 311 Island Avenue, San Diego, California. The meeting is open to the public, with limited seating on a first-come, first-served basis.

**FOR FURTHER INFORMATION CONTACT:** Mr. Robert Hardaker, Designated Federal Officer, U.S. EPA, Office of Cooperative Environmental Management, telephone 202-260-2477.

Dated: February 9, 1998.

**Robert Hardaker,**

*Designated Federal Officer, Governmental Advisory Committee.*

[FR Doc. 98-4938 Filed 2-25-98; 8:45 am]

BILLING CODE 6560-50-P

---

## FEDERAL COMMUNICATIONS COMMISSION

### Public Information Collection(s) Approved by Office of Management and Budget

February 19, 1998.

The Federal Communications Commission (FCC) has received Office of Management and Budget (OMB) approval for the following public information collection(s) pursuant to the Paperwork Reduction Act of 1995, 44 USC 3501-3520. An agency may not conduct or sponsor a collection of information unless it displays a currently valid control number. Notwithstanding any other provisions of law, no person shall be subject to any penalty for failing to comply with a collection of information subject to the Paperwork Reduction Act (PRA) that does not display a valid control number. Questions concerning the OMB control numbers and expiration dates should be directed to Jerry Cowden, Federal Communications Commission, (202) 418-0447.

### Federal Communications Commission.

*OMB Control No.:* 3060-0291.

*Expiration Date:* 2/28/2001.

*Title:* 90.477 Interconnected systems.

*Form Number:* Not

applicable. Estimated annual burden: 1,000 hours; 1 hour per response; 1,000 respondents.

*Description:* This section allows private land mobile radio licensees to use common point telephone interconnection with telephone service costs distributed on a non-profit cost sharing basis. Records of such arrangements must be placed in the licensee's station records and made available to participants in the sharing arrangement and the Commission upon request.

*OMB Control No.:* 3060-0224.

*Expiration Date:* 2/28/2001.

*Title:* 90.151 Requests for waiver.

*Form Number:* Not applicable.

*Estimated Annual Burden:* 120 hours; 2 hours per respondent; 60 respondents.

*Description:* The Commission has the responsibility to establish and administer rules for the orderly and efficient use of the radio spectrum. Circumstances do arise, however, where general rules cannot properly address the needs of the public, and waiver of those rules is desirable. In order to enable the Commission to make an informed decision on the desirability of such waivers, applicants are required to submit information justifying why a waiver is needed.

*OMB Control No.:* 3060-0226.

*Expiration Date:* 2/28/2001.

*Title:* 90.135(d) & (e) Modification of license.

*Form Number:* Not

applicable. Estimated Annual Burden: 276 hours; 0.167 hour per respondent; 1,656 respondents.

*Description:* These rule paragraphs require licensees who have changed their name, address, number and location of station control points, number of mobile units, interconnection status, and/or sharing status to notify the Commission. This information collection applies only to licensees who elect to inform the Commission by letter of these changes. Licensees may also use forms to notify us of these changes. Notification is necessary to maintain an accurate database that is used by both the Commission, frequency coordinators and the public in corresponding with licensees regarding interference resolution and licensing matters.

*OMB Control No.:* 3060-0281.

*Expiration Date:* 2/28/2001.

*Title:* 90.651 Supplemental reports required of licensees authorized under this subpart.

*Form Number:* Not applicable.  
*Estimated Annual Burden:* 2,724 hours; 0.166 hour per respondent; 16,408 respondents.

*Description:* The radio facilities addressed in this subpart of the rules are allocated on and governed by regulations designed to award facilities on a need basis determined by the number of mobile units served by each base station. This is necessary to avoid frequency hoarding by applicants. This rule section requires licensees to report the actual number of mobile units served. The various subparagraphs of this rule apply to different categories of licensees and define exactly what reports are required of each category.

Federal Communications Commission.

**Magalie Roman Salas,**

*Secretary.*

[FR Doc. 98-4914 Filed 2-25-98; 8:45 am]

BILLING CODE 6712-01-F

---

## FEDERAL COMMUNICATIONS COMMISSION

[Report No. 2256]

### Petitions for Reconsideration and Clarification of Action in Rulemaking Proceedings

February 23, 1998.

Petitions for reconsideration and clarification have been filed in the Commission's rulemaking proceedings listed in this Public Notice and published pursuant to 47 CFR Section 1.429(e). The full text of these documents are available for viewing and copying in Room 239, 1919 M Street, N.W., Washington, D.C. or may be purchased from the Commission's copy contractor, ITS, Inc. (202) 857-3800. Oppositions to these petitions must be filed by March 13, 1998. See Section 1.4(b)(1) of the Commission's rule (47 CFR 1.4(b)(1)). Replies to an opposition must be filed within 10 days after the time for filing oppositions has expired.

*Subject:* Amendment of Part 1 of the Commission's Rules—Competitive Bidding Procedures (WT Docket No. 97-82)

*Number of Petitions Filed:* 7

Federal Communications Commission.

**Magalie Roman Salas,**

*Acting Secretary.*

[FR Doc. 98-4915 Filed 2-25-98; 8:45 am]

BILLING CODE 6712-01-M

---

## FEDERAL ELECTION COMMISSION

### Sunshine Act Meeting

**AGENCY:** Federal Election Commission.

**DATES AND TIME:** Tuesday, March 3, 1998 at 10:00 a.m.

**PLACE:** 999 E Street, N.W., Washington, D.C.

**STATUS:** This meeting will be closed to the public.

**TIMES TO BE DISCUSSED:**

Compliance matters pursuant to 2

U.S.C. § 437g.

Audits conducted pursuant to 2 U.S.C.

§ 437g, § 438(b), and Title 26, U.S.C.

Matters concerning participation in civil actions or proceedings or arbitration.

Internal personnel rules and procedures or matters affecting a particular employee.

**DATE AND TIME:** Thursday, March 5, 1998 at 2:00 p.m.

**PLACE:** 999 E Street, N.W., Washington, D.C. (ninth floor).

**STATUS:** This meeting will be open to the public.

**ITEMS TO BE DISCUSSED:**

Correction and Approval of Minutes. Advisory Opinion 1997-28: W. Ben Bius.

Advisory Opinion 1998-02: Reform Party of the United States of America, by Russell J. Verney, Chairman.

Advisory Opinion 1998-03: Reform Party of Idaho, by Gary G. Allen, Chairman.

Audit: San Diego Host Committee/Sail to Victory '96 (continued from meeting of February 26, 1998).

Audit: Committee on Arrangements for the 1996 Republican National Convention (continued from meeting of February 26, 1998).

Legislative Recommendation—1998 (continued from Meeting of February 26, 1998).

Administrative Matters.

**PERSON TO CONTACT FOR INFORMATION:**

Mr. Ron Harris, Press Officer, Telephone: (202) 219-4155.

**Marjorie W. Emmons,**

*Secretary of the Commission.*

[FR Doc. 98-5083 Filed 2-24-98; 12:12 pm]

BILLING CODE 6715-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Joint Meeting of the Dermatologic and Ophthalmic Drugs Subcommittee and the Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of public advisory committees of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committees:* Joint meeting of the Dermatologic and Ophthalmic Drugs Subcommittee and the Endocrinologic and Metabolic Drugs Advisory Committee.

*General Function of the Committees:* To provide advice and recommendations to the agency on FDA regulatory issues.

*Date and Time:* The meeting will be held on March 11, 1998, 8 a.m. to 5 p.m.

*Location:* Holiday Inn, Walker Room, Two Montgomery Village Ave., Gaithersburg, MD.

*Contact Person:* Tracy Riley or Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), codes 12534 and 12536. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The committee will discuss scientific clinical trial design for products intended for the treatment of diabetic retinopathy.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 4, 1998. Oral presentations from the public will be scheduled between approximately 8 a.m. and 8:30 a.m., and between approximately 1 p.m. and 1:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 4, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

FDA regrets that it was unable to publish this notice 15 days prior to the joint meeting of the Dermatologic and Ophthalmic Drugs Subcommittee and the Endocrinologic and Metabolic Drugs Advisory Committee. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Dermatologic and Ophthalmic Drugs Subcommittee and the Endocrinologic and Metabolic

Drugs Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 20, 1998.

**Michael A. Friedman,**

*Deputy Commissioner for Operations.*

[FR Doc. 98-5050 Filed 2-24-98; 11:42 am]

BILLING CODE 4160-01-F

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Vaccines and Related Biological Products Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

*Name of Committee:* Vaccines and Related Biological Products Advisory Committee.

*General Function of the Committee:*

To provide advice and recommendations to the agency on FDA regulatory issues.

*Date and Time:* The meeting will be held on March 23, 1998, 7:45 a.m. to 6:20 p.m.

*Location:* Ramada Inn, Embassy Ballroom, 8400 Wisconsin Ave., Bethesda, MD.

*Contact Person:* Nancy T. Cherry or Denise H. Royster, Center for Biologics Evaluation and Research (HFM-21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12391. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The committee will: (1) Discuss scientific and ethical considerations of a human challenge model using virulent *Salmonella typhi* bacteria; (2) complete recommendations pertaining to the influenza virus vaccine formulation for 1998 and 1999; and (3) hear short briefings on research programs in the Laboratories of DNA Viruses, Hepatitis Viruses, and Bacterial Polysaccharides.